Centessa Pharmaceuticals plc
3rd Floor, 1 Ashley Rd,
Altrincham, Cheshire,
United Kingdom, WA14 2DT
July 8, 2022
Via EDGAR Transmission
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Centessa Pharmaceuticals plc: Registration Statement on Form S-3 filed July 1, 2022 (File No. 333-265978) |
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Centessa Pharmaceuticals plc (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to July 12, 2022, at 4:00 pm Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
If you have any questions regarding this request, please contact James Xu of Goodwin Procter LLP at (650) 752-3355.
| Sincerely, |
| Centessa Pharmaceuticals plc |
| /s/ Saurabh Saha |
| Saurabh Saha, M.D., Ph.D. |
| Chief Executive Officer |
| cc: |
Iqbal Hussain, Centessa Pharmaceuticals plc | |
| Gregory Weinhoff, Centessa Pharmaceuticals plc | ||
| Mitchell Bloom, Goodwin Procter LLP | ||
| James Xu, Goodwin Procter LLP |